caltrate with vitamin d 600 tablets (Pfizer Inc)
90
Structured Review
Pfizer Inc
caltrate with vitamin d 600 tablets
Caltrate With Vitamin D 600 Tablets, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caltrate+with+vitamin+d+600+tablets/caltrate+with+vitamin+d+600+tablets/pm29266368-71-11-21
Average 90 stars, based on 1 article reviews
Caltrate With Vitamin D 600 Tablets, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caltrate+with+vitamin+d+600+tablets/caltrate+with+vitamin+d+600+tablets/pm29266368-71-11-21
Average 90 stars, based on 1 article reviews
caltrate with vitamin d 600 tablets - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women. Article Snippet: 2016 Aim: To investigate the correlation between DKK1 polymorphisms with bone phenotypes and response to alendronate treatment.. Materials & methods: Five tag single nucleotide polymorphisms of DKK1 were analyzed in 639 Chinese postmenopausal women with osteoporosis or osteopenia.. Bone mineral density (BMD), β-CTX and ALP were measured before and after alendronate treatment. Article Title: SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. Article Snippet: All women were supplemented with 600 mg Article Title: LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. Article Snippet: Osteoporosis is a common disease that is char acterized by low bone mineral density (BMD), deteriorated bone microarchitecture and increased risk of fractures.. Genetic factors play an important role in osteoporosis and contribute towards 60–80% of the variance in BMD [1,2].. However, genetic determinants of the response to antiosteoporotic treatment are still unclear. Article Title: Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Article Snippet: Objective: The aim of this study was to evaluate the effect of low-dose alendronate (ALN) treatment on bone mineral density (BMD) and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.. Methods: This study was a large-sample, randomized, open-label, prospective, multicenter, clinical trial with a 12-month follow-up.. A total of 639 postmenopausal women (aged 62.2 T 7.0 y) with osteopenia or osteoporosis were randomized into two groups: low-dose ALN (70 mg every two weeks) and standard-dose ALN (70 mg weekly). Article Title: Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment. Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/cen.13537 This article is protected by copyright.. All rights reserved. |